Loop Capital started coverage on shares of Tempus AI (NASDAQ:TEM – Free Report) in a report published on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $48.00 price objective on the stock.
Separately, JPMorgan Chase & Co. initiated coverage on Tempus AI in a report on Tuesday. They set an overweight rating and a $42.00 price target on the stock. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of Buy and an average target price of $45.63.
Read Our Latest Stock Report on Tempus AI
Tempus AI Stock Performance
About Tempus AI
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
- Five stocks we like better than Tempus AI
- What is Short Interest? How to Use It
- Sales Breakout Sends This Semiconductor Stock to Record High
- What Are the FAANG Stocks and Are They Good Investments?
- Surprise Buying Opportunity on This Dividend Aristocrat
- Do ETFs Pay Dividends? What You Need to Know
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
